Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$75,898.00-1.58%ETH$2,405.51-3.20%GOLD$4,390.60+1.33%OIL$103.24-2.45%
Smart Investors Daily
TE

NYSE · TEVA

Teva Pharmaceutical Industries Limited

Healthcare · Drug Manufacturers - Specialty & Generic

$39.25

Up+$0.53 (+1.37%)

Updated Sep 16, 2026, 10:49 AM

SID Score

6.7/10

Composite research score

Smart Money

60/100

Neutral

Market cap
34.61B
P/E ratio
-217.43
Dividend yield
0.00%
52-week range
$18.21 – $39.22
Volume
7.13M
Avg. volume
11.34M

Price performance

TEVA price history

1M range · 20 trading sessions · Daily adjusted prices

TEVA closed at $39.25 after 20 trading sessions, up 7.30% for the selected period.

Last close
$39.25
Period change
+7.30%
Period low
$36.05
Period high
$39.25
Daily close
View OHLC price history
TEVA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$38.71$39.49$38.11$39.257.13M
Sep 14, 2026$37.66$39.22$37.00$38.724.38M
Sep 11, 2026$36.46$37.11$36.06$37.092.86M
Sep 10, 2026$36.37$36.75$36.04$36.354.01M
Sep 9, 2026$36.82$37.315$36.47$36.854M
Sep 8, 2026$35.89$36.965$35.42$36.764.62M
Sep 4, 2026$36.40$36.93$36.13$36.367.4M
Sep 3, 2026$37.98$38.06$36.33$36.623.9M
Sep 2, 2026$36.65$37.59$35.742$37.497.69M
Sep 1, 2026$36.52$36.55$35.85$36.193.52M
Aug 31, 2026$36.17$36.3347$35.62$36.055.78M
Aug 28, 2026$37.37$37.42$36.37$36.443.14M
Aug 27, 2026$37.72$38.37$37.535$37.624.72M
Aug 26, 2026$37.70$38.055$37.07$37.924.82M
Aug 25, 2026$37.13$38.11$37.09$38.105.28M
Aug 24, 2026$37.30$37.32$36.75$36.933.34M
Aug 21, 2026$36.79$37.75$36.65$37.344.3M
Aug 20, 2026$37.12$37.345$36.735$36.814.51M
Aug 19, 2026$37.00$37.83$36.6034$37.477.98M
Aug 18, 2026$36.47$37.25$36.34$36.586.2M

Latest TEVA news

The latest Smart Investors Daily articles mentioning TEVA.

Stock researchCompany · Overview

TEVA research

Overview

Company profile and research snapshot.

Company profile

Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$32.67
Implied upside
—
Analysts
—
TEVA recent ratings
DateFirmRatingTarget
Nov 25, 2020OppenheimerPerform—
Nov 6, 2020BMO CapitalMarket Perform—
Aug 6, 2020SVB LeerinkMarket Perform—
Aug 6, 2020BarclaysEqual-Weight—
Jul 27, 2020Goldman SachsNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 10, 2026

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes

TEL AVIV, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully priced its offering of approximately $4.9 billion (equivalent) of senior notes (the “Notes”). Teva expects to use the net proceeds from the offering, together with cash on hand, (i) to fund the redemptions of certain existing notes as further set out below (the “Conditional Redemptions”), (ii) to pay fees and expenses in connection therewith

Benzinga · Sep 10, 2026

Teva Priced Approximately $4.9B (Equivalent) of Senior Notes

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today that it successfully priced its offering of approximately $4.9 billion (equivalent) of senior notes (the "Notes"). Teva

Yahoo · Sep 7, 2026

Teva Announces Launch of Offering of Senior Notes

TEL AVIV, Israel, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue senior notes through its special purpose finance subsidiaries. Teva Pharmaceutical Finance Netherlands II B.V. (“Teva Finance II”) intends to offer EUR-denominated Senior Notes (the “Euro Notes”) and Teva Pharmaceutical Finance Netherlands III B.V. (“Teva Finance III”) and Teva Pharmaceutical Finance Netherlands IV B.V. (“Teva Finance IV”

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By